Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139902 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by Diwakar Davar.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT04139902 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is active but no longer recruiting, run by Diwakar Davar. The registered enrollment target is 48 participants, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (52% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT04139902, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is active but no longer recruiting, sponsored by Diwakar Davar.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
Conditions Studied
Interventions
- DRUG Dostarlimab (TSR-042) (singly)
- DRUG Dostarlimab (TSR-042) and TSR-022 (combination)
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
- UPMC Hillman Cancer Center Washington - Washington
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2029-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139902
The ClinicalTrials.gov registry entry for NCT04139902 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (52% lower). The listed sponsor is Diwakar Davar, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 2 interventions - of which Dostarlimab (TSR-042) (singly) is the first listed.
NCT04139902 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04139902 about?
NCT04139902 is a clinical study titled "Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma". The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
What is the current status of trial NCT04139902?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-06-12. Estimated completion is 2029-12-15.
What conditions does trial NCT04139902 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III.
What interventions are being tested in trial NCT04139902?
The interventions under investigation include: Dostarlimab (TSR-042) (singly) (DRUG), Dostarlimab (TSR-042) and TSR-022 (combination) (DRUG).
Who is sponsoring clinical trial NCT04139902?
This trial is sponsored by Diwakar Davar, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04139902 being conducted?
This trial has 5 study locations across District of Columbia, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.